Method for detecting muscle degenerative diseases, and method for determining therapeutic efficacy on the diseases
US8658390B2 · kind B2 · utility
0Cited by
1References
4Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Mar 8, 2010 |
| Grant date | Feb 25, 2014 |
| Priority date | — |
| Expiry date | Mar 8, 2030 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/2878
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
Muscle degenerative diseases can be detected in the early stage and the therapeutic efficacy of a therapeutic agent and/or a therapy method for the diseases can be determined by measuring 11,15-dioxo-9α-hydroxy-2,3,4,5-tetranorprostan-1,20-dioic acid (referred to as “Tetranor-PGDM”, hereinbelow) in a sample isolated from a subject.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.